Different regions of the brain and spinal cord house different, specialized cells. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from each of these regions of the developing central nervous system (CNS) in virtually unlimited numbers from a single donated tissue. More

Neuralstem’s technology uniquely enables the creation of stable neural stem cell lines from the human hippocampus, a part of the brain involved in memory and the generation of new neurons. From these cell lines, the company can create practically unlimited amounts of hippocampal neural stem cells. More

    • Jonathan Lloyd Jones Appointed CFO 5.6.15

      Former CFO and/or VP of three biotech/ pharma companies and former Senior Director, Corporate Development, for Genzyme brings expertise in corporate finance, licensing, and partnering. More

    • NSI-566 ALS Phase II Topline Results Announced 3.12.15

      Cervical intervention deemed safe, 16 million cells maximum tolerated dose established, and secondary efficacy endpoints reviewed. More

          • NSI-189/MDD Neurogenic Biomarker Data Presented 11.17.14

            Depression blood-based biomarker analysis presented at CNS Summit shows NSI-189 rapidly and persistently efficacious. More

          • “The Moments You Live For” 11.12.14

            Dr. Eva Feldman’s clinical and pre-clinical work underway with Neuralstem’s neural stem cell platform technology to treat neurodegenerative disorders is featured in The Detroit News. More

          • NSI-566/ALS Study Shows Long-term Cell Survival and Differentiation 11.10.14

            Scientific data shows cells survive up to 2.5 years and suggests continued immunosuppression not required for transplanted cell survival. More

          • First Data on Alzheimer’s Disease
            Cell Therapy Presented 10.23.14

            Neuralstem’s NSI-532.IGF cells rescued spatial learning and memory deficits in animal data presented by University of Michigan at the Congress of Neurological Surgeons Annual Meeting. More

          • Neuralstem’s CEO BioWorld Interview on NSI-566/cSCI 10.10.14

            Richard Garr discusses the promise, similarities and differences of NSI-566 cell therapy for the second FDA-approved U.S. trial indication: chronic spinal cord injury, now underway in Phase I. More

          • First Spinal Cord Injury Phase I Patient Treated at UCSD 10.9.14

            Second indication in U.S. using NSI-566 stem cells adds structural repair mechanism of action, “bridging the circuitry gap,” to neuroprotective factor expression demonstrated in ALS trials. More

          • Dr. Eva Feldman to determine how NSI-566 “slows down the progression” of ALS in trial patients 8.1.14

            NSI-566/ALS’s principal investigator also shares insights into Neuralstem’s upcoming ALS registration trial, and just-concluded animal research on Alzheimer’s disease. More

          • EEG Findings Show NSI-189 Measurable Impact on Hippocampal Region in
            Phase I Trial 6.19.14

            Researchers report that neurogenic NSI-189 increased high-frequency brain wave activity in the left temporal region, where the hippocampus is located, in NSI-189/MDD select data to be presented at CINP World Congress. More

          • Neurogenic NSI-189 Phase I Data Heralds First-time Depression Field Findings 6.18.14

            Mass Gen/Harvard’s Dr. Marlene Freeman presents data, showing significant effect size in antidepressant activity and cognitive function improvement spanning NSI-189/MDD trial duration, at ASCP Annual Meeting. More

          • CNN’s Miriam Falco Reports on NSI-566 Promise for Spinal Cord Injuries 4.16.14

            Neuralstem’s Karl Johe, PhD and Richard Garr give insights on the ability of NSI-566 to "actually build new circuitry” and “jump the gap with the new circuitry we've built.” More

          • NSI-566/Stroke Study Published 3.28.14

            Science journal, PLOS ONE, publishes USF rat study showing significant improvement post-stroke and validates cell survival and functionality in the brain. More

          • NSI-566/ALS Final Phase I Data 3.17.14

            Annals of Neurology first to report outcomes of cervical and dual-targeted NSI-566 transplantations, which show Neuralstem’s cells replace lost cells, provide neurotrophic support, and improve the diseased microenvironment. More

          • NSI-566/Stroke: “A crucial step forward for the field at large…” 2.5.14

            “Optimizing cell therapy treatment for CNS indications will require delivering cells to the brain, as well as to the spinal cord.” - Neuralstem's CSO, Dr. Johe, quoted in a BioWorld article. More

          • NSI-566 Reverses Cognitive Defect in Brain-Irradiated Animals 8.1.13

            Transplanted rats improved hippocampal spatial memory as well as intact amygdala function, in model similar to clinical irradiation intervention given to treat brain cancer patients, in published paper by UC Irvine researchers. More

          • NSI-566 Induce Improvement in Acute Spinal Cord Injury Rats Three Days Post-Injury 5.28.13

            Latest published research from UCSD's Dr. Marsala demonstrates that intraspinal grafting of NSI-566 cells during the acute SCI phase could represent an effective treatment that ameliorates post-injury motor and sensory deficits. UCSD cited as a center in Neuralstem's upcoming 2013 cSCI clinical trial. More